Peptides like Ipamorelin and CJC-1295 can naturally stimulate your bodys own production of growth hormone, aiding in fat loss, muscle growth, and recovery
Detailed Product Description Retatrutide is a novel investigational medication classified as a triple hormone receptor agonist
Segalen C, Longnus SL, Baetz D, Counillon L, Van Obberghen E (2008) 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside reduces glucose uptake via the inhibition of Na+/H+ exchanger 1 in isolated rat ventricular cardiomyocytes
What the study found In patients with obesity + HFpEF, semaglutide and tirzepatide showed similar rates of: all-cause death HF hospitalization and the composite outcome (death + HF hospitalization) Key numbers TriNetX federated EHR analysis 3,983 patients total 1:1 propensity-matched: 1,258 vs 1,258 Median follow-up: 24 weeks Primary composite outcome: HR 1.14 (95% CI 0.891.46), p=0.286 My take For cardio-obesity HFpEF care, this is a useful reminder: Drug selection is often aboutthe right patient, the right goal, the right contextnot just which agent gives more weight loss. So in practice, choice may be driven by: tolerability access/cost glycaemic needs comorbidities patient adherence preferences Important caveat: this is retrospective observational EHR data (not a randomized head-to-head trial), with short follow-up
Saez-Llorens X, Yogev R, Arguedas A, et al
